The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.
CBC
COVID-19
SII
coronavirus
inflammation
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
04 Dec 2020
04 Dec 2020
Historique:
received:
18
11
2020
revised:
30
11
2020
accepted:
01
12
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
The rapid onset of a systemic pro-inflammatory state followed by acute respiratory distress syndrome is the leading cause of mortality in patients with COVID-19. We performed a retrospective observational study to explore the capacity of different complete blood cell count (CBC)-derived inflammation indexes to predict in-hospital mortality in this group. The neutrophil to lymphocyte ratio (NLR), derived NLR (dNLR), platelet to lymphocyte ratio (PLR), mean platelet volume to platelet ratio (MPR), neutrophil to lymphocyte × platelet ratio (NLPR), monocyte to lymphocyte ratio (MLR), systemic inflammation response index (SIRI), systemic inflammation index (SII), and the aggregate index of systemic inflammation (AISI) were calculated on hospital admission in 119 patients with laboratory confirmed COVID-19. Non-survivors had significantly higher AISI, dNLR, NLPR, NLR, SII, and SIRI values when compared to survivors. Similarly, Kaplan-Meier survival curves showed significantly lower survival in patients with higher AISI, dNLR, MLR, NLPR, NLR, SII, and SIRI. However, after adjusting for confounders, only the SII remained significantly associated with survival (HR = 1.0001; 95% CI, 1.0000-1.0001, The SII on admission independently predicts in-hospital mortality in COVID-19 patients and may assist with early risk stratification in this group.
Sections du résumé
BACKGROUND
BACKGROUND
The rapid onset of a systemic pro-inflammatory state followed by acute respiratory distress syndrome is the leading cause of mortality in patients with COVID-19. We performed a retrospective observational study to explore the capacity of different complete blood cell count (CBC)-derived inflammation indexes to predict in-hospital mortality in this group.
METHODS
METHODS
The neutrophil to lymphocyte ratio (NLR), derived NLR (dNLR), platelet to lymphocyte ratio (PLR), mean platelet volume to platelet ratio (MPR), neutrophil to lymphocyte × platelet ratio (NLPR), monocyte to lymphocyte ratio (MLR), systemic inflammation response index (SIRI), systemic inflammation index (SII), and the aggregate index of systemic inflammation (AISI) were calculated on hospital admission in 119 patients with laboratory confirmed COVID-19.
RESULTS
RESULTS
Non-survivors had significantly higher AISI, dNLR, NLPR, NLR, SII, and SIRI values when compared to survivors. Similarly, Kaplan-Meier survival curves showed significantly lower survival in patients with higher AISI, dNLR, MLR, NLPR, NLR, SII, and SIRI. However, after adjusting for confounders, only the SII remained significantly associated with survival (HR = 1.0001; 95% CI, 1.0000-1.0001,
CONCLUSIONS
CONCLUSIONS
The SII on admission independently predicts in-hospital mortality in COVID-19 patients and may assist with early risk stratification in this group.
Identifiants
pubmed: 33291581
pii: molecules25235725
doi: 10.3390/molecules25235725
pmc: PMC7731255
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione di Sardegna, Sassari, Italy
ID : Prat. 2016.0917
Références
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474
pubmed: 32818235
Epidemiol Infect. 2020 Jul 09;148:e139
pubmed: 32641174
Int J Lab Hematol. 2020 Dec;42(6):780-787
pubmed: 32779860
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
Intensive Care Med. 2020 Oct 29;:
pubmed: 33211135
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
BMC Infect Dis. 2020 Nov 23;20(1):869
pubmed: 33225909
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Lab Anal. 2020 Oct;34(10):e23475
pubmed: 32681559
Lung. 2020 Oct;198(5):821-827
pubmed: 32844257
Clin Microbiol Infect. 2020 Oct;26(10):1400-1405
pubmed: 32622952
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Leukemia. 2020 Aug;34(8):2173-2183
pubmed: 32546725
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Oncotarget. 2020 Jul 07;11(27):2625-2635
pubmed: 32676164
Thromb Haemost. 2020 Sep 22;:
pubmed: 32961572
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect. 2020 Jul;81(1):e95-e97
pubmed: 32305490
J Med Virol. 2020 Jul;92(7):719-725
pubmed: 32170865
Cancer Immunol Immunother. 2018 Sep;67(9):1349-1353
pubmed: 29947960
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Crit Care. 2020 Dec;60:32-37
pubmed: 32736197
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
ERJ Open Res. 2020 Apr 27;6(2):
pubmed: 32363205
J Transl Med. 2020 Jul 3;18(1):270
pubmed: 32620125
Eur J Gastroenterol Hepatol. 2020 Aug 10;:
pubmed: 32796355
Cells. 2020 Jun 02;9(6):
pubmed: 32498376
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347201
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
J Med Virol. 2020 Oct;92(10):2188-2192
pubmed: 32436996
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Ther Adv Med Oncol. 2020 Jul 11;12:1758835920937425
pubmed: 32699557
Tohoku J Exp Med. 2015;236(4):297-304
pubmed: 26250537
Clin Infect Dis. 2020 Jul 28;71(15):833-840
pubmed: 32296824
Shock. 2020 Nov;54(5):652-658
pubmed: 32554992
J Clin Med Res. 2020 Jul;12(7):448-453
pubmed: 32655740
Clin Exp Med. 2019 Feb;19(1):37-45
pubmed: 30478648
Isr Med Assoc J. 2020 May;22(5):271-274
pubmed: 32378815
Eur J Clin Invest. 2018 Aug;48(8):e12984
pubmed: 29924383
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect Dev Ctries. 2020 Jul 31;14(7):685-690
pubmed: 32794454
J Med Virol. 2020 Oct;92(10):1922-1931
pubmed: 32297985
Biomark Med. 2020 Sep;14(13):1207-1215
pubmed: 32692248
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994